Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material
09 Setembro 2024 - 5:32PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
SCHEDULE
14A
Proxy
Statement Pursuant to Section 14(a) of the Securities and Exchange Act of 1934
Filed
by the Registrant ☒ |
Filed
by a Party other than the Registrant ☐ |
Check
the appropriate box: |
☐ |
Preliminary
Proxy Statement |
☐ |
Confidential,
for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) |
☐ |
Definitive
Proxy Statement |
☒ |
Definitive
Additional Materials |
☐ |
Soliciting
Material Pursuant to § 240.14a-12 |
ZYVERSA
THERAPEUTICS, INC. |
(Name
of Registrant as Specified in Its Charter)
|
(Name of Person(s) Filing
Proxy Statement, if other than the Registrant) |
Payment of Filing Fee (Check the appropriate
box): |
|
☒ |
No fee required |
☐ |
Fee paid previously with preliminary materials |
☐ |
Fee computed on table in exhibit required by Item 25(b)
per Exchange Act Rules 14a-6(i)(1) and 0-11 |
ZyVersa Therapeutics (NASDAQ:ZVSA)
Gráfico Histórico do Ativo
De Jan 2025 até Fev 2025
ZyVersa Therapeutics (NASDAQ:ZVSA)
Gráfico Histórico do Ativo
De Fev 2024 até Fev 2025